EUROPEAN PATENT SPECIFICATION

Use of bilobalide and derivatives thereof for treating an infection in an individual and pharmaceutical compositions adapted for such use

Verwendung von Bilobalid und deren Derivate zur Behandlung von Infektionen bei Menschen und für eine solche Anwendung geeignete pharmazeutische Zusammensetzung

Utilisation du bilobalide et de ses dérivés dans le traitement parti-infecctieux chez un individu et composition pharmaceutique adaptée à une telle utilisation

Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

Priority: 13.02.1992 GB 9202993

Date of publication of application: 18.08.1993 Bulletin 1993/33

Proprietor: INDENA S.p.A.
20141 Milano (IT)

Inventors:
• Bombardelli, Ezio
I-20141 Milano (IT)
• Ghione, Mario
I-20161 Milano (IT)

Representative: Ritter, Stephen David et al
Mathys & Squire
100 Grays Inn Road
London WC1 X 8AL (GB)

References cited:
EP-A- 0 143 977
EP-A- 0 441 279

PLANTES MEDICINALES ET PHYTOTHERAPIE vol. 19, no. 4, 1985, pages 270 - 276 M. MOUREY ET AL. 'ACTIVITE ANTIMICROBIENNE D'EXTRAITS DE FEUILLES DE GINKGO BILOBA'


LIEBIGS ANN. CHEM. vol. 759, 1972, pages 158 - 172 K. WEINGES ET AL. 'NMR-UND MASSENSPEKTROMETRISCHER VERGLEICH DES BIOLALIDS C15H18O6 MIT DEN GINKGOLIDEN C20H24O9-11'

Remarks:
The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).
This invention relates to novel pharmaceutical uses of bilobalide and derivatives thereof, and to pharmaceutical compositions adapted for such use.

Bilobalide is a sesquiterpene of formula

which may be extracted from leaves of the tree Ginkgo biloba.


Recently various medical applications have been proposed for bilobalide in the treatment of pathological conditions of the nervous system. For example US-A-4,892,883 and EP-A-0 143 977 describe the pharmacological use of bilobalide in the treatment of neuropathies, inflammatory conditions and immunodeficient and neurological conditions of traumatic origin. EP-A-0 441 279 describes the use of bilobalide derivatives, particularly complexes with phospholipids, in the treatment of peripheral disorders associated with inflammatory and neurodystrophic alterations.

No other useful biological effects have been reported and, in fact, EP-A-0 143 977 specifically states that bilobalide has no antifungal action against Monilia fructicola or Penicillium glaucum and no antibacterial action against Escherichia coli.

The prior art also includes documents such as Mourey, M. et al, "Activité Antimicrobienne d'Extrait de Feuilles de Ginkgo Biloba L.", Plantes médicinales et phytothérapie 1985, Tome XIX, No.4, p.270-276, which describe the antimicrobial activity of extracts of Ginkgo biloba leaves by diffusion in an agar medium. Neither putative activities of individual components of the, nor in vivo effects are described.

It is thus extremely surprising that following an extensive investigation of the biological properties of bilobalide, it has been found that bilobalide and derivatives thereof may be used in the treatment of infections with pathological strains of a variety of diverse pathogenic bacterial, fungal and protozoal organisms.

Thus according to one aspect of the present invention there is provided a method of treating an infection in an individual, which comprises administering to the individual via a route of administration which delivers it to the site of infection, an effective dose of bilobalide or of a pharmacologically acceptable derivative thereof. Bilobalide may be administered systemically or topically in accordance with the invention. For systemic use, oral and parenteral routes of administration may be used.

The invention further provides the use of bilobalide or of a pharmacologically acceptable derivative thereof in the manufacture of a pharmaceutical composition for treating an infection in an individual.

Thus in the course of an extensive screening program it has surprisingly been found that bilobalide and derivatives thereof are active in vitro against colonies of pathological strains of organisms including Trichomonas vaginalis, Staphylococcus aureus, Streptococcus faecalis, Escherichia coli, Lactobacillus sp., Pneumocystis carinii and that useful in vivo antibiotic activity has also been observed.

In view of these activities, bilobalide and pharmacologically acceptable derivatives thereof provide valuable therapeutic agents for use where existing treatments are ineffective, non-existent, or associated with undesirable side-effects.

Thus for example bilobalide has been found to be active against Trichomonas vaginalis. Although the action of bilobalide on Trichomonas vaginalis is less powerful than that of the 5-nitro-imidazole derivatives (highly potent drugs used against T vaginalis and other protozoa) the latter suffer the disadvantage of being poorly tolerated by some individuals who can display allergic reactions to the known drugs. The use of bilobalide to treat such patients enables the problem of sensitivity to 5-nitro-imidazole derivatives to be avoided. A further factor rendering bilobalide worthy of investigation is its action on Lactobacillus sp.

Bilobalide has in fact proved to be very effective in reducing infections caused by these parasites in the vaginal milieu, where lactobacilli and flagellates form part of the biocenosis and also in the treatment of periodontal infections. It is also extremely well tolerated.

Thus according to a further, more specific aspect of the present invention there is provided a method of treating a vaginal infection in an individual, which comprises administering an effective dose of bilobalide or of a pharmacologi-
cally acceptable derivative thereof to the vagina.

The invention further provides the use of bilobaide or of a pharmacologically acceptable derivative thereof in the manufacture of a pharmaceutical composition for treating a vaginal infection in an individual. For such applications, the bilobaide or a pharmacologically acceptable derivative thereof is conveniently administered in the form of a pessary or vaginal suppository, or as a cream or gel adapted for vaginal administration.

According to a further aspect of the present invention there is provided a method of treating a periodontal infection in an individual, which comprises administering an effective dose of bilobaide or of a pharmacologically acceptable derivative thereof to the mouth. In this embodiment the invention further provides the use of bilobaide or of a pharmacologically acceptable derivative thereof in the manufacture of a pharmaceutical composition for treating a periodontal infection in an individual. For such applications, the bilobaide or a pharmacologically acceptable derivative thereof is conveniently administered in the form of a toothpaste, mouth-wash or other orally acceptable composition.

Bilobaide and pharmaceutically acceptable derivatives thereof has also been found to exhibit an antibiotic effect against *Pneumocystis carinii*, a microorganism which is the causative organism of pneumonia in immunologically impaired individuals.

*Pneumocystis carinii* is a microorganism the taxonomic classification of which causes some disagreement (most sources classifying it as a protozoan, but some classify it as a fungus). *Pneumocystis carinii* is known to be responsible for fatal cases of pneumonia in patients exhibiting immuno-suppression, particularly patients infected with HIV and exhibiting to a greater or lesser extent, the symptoms associated with AIDS. The activity of bilobaide against this organism thus makes it a promising drug for treating AIDS sufferers, thus making its use of highly topical significance.

The recently introduced culture of this parasite is helping the study of new drugs and comparisons with existing drugs. In our experiments bilobaide was compared with cotrimoxazole, over which it has valuable therapeutic advantages. In vitro, in concentrations exceeding 12 µg/ml (active concentration), bilobaide exerts an effect equal to the reference substance, but in higher doses its effect is definitively superior, indicating that the dose-effect curve is not parallel but superior to that of cotrimoxazole.

In vivo the maximum dose of bilobaide that can be tolerated is 100 mg/kg for 5 days i.p. A dose of 10 mg/kg is well tolerated and significantly reduces disease in experimental animals.

Thus according to a further aspect of the present invention there is provided a method of treating an infection in an individual with *Pneumocystis carinii*, which comprises administering an effective dose of bilobaide or of a pharmacologically acceptable derivative thereof.

The invention further provides the use of bilobaide or of a pharmacologically acceptable derivative thereof in the manufacture of a pharmaceutical composition for treating a pulmonary infection in an individual, especially an individual suffering an infection with *Pneumocystis carinii*.

Examples of pharmacologically acceptable derivatives of bilobaide which may be used in accordance with the invention are esters, for example esters in which one or both of the hydroxy groups of bilobaide are esterified with an acid such as a C_{22} fatty acid. Such esters include esters with C_{22} alkyl alcohols, C_{22} alkyl acids and C_{22} alkadienic acids. Such acids have the formulae C_{n}H_{2n+1}COOH, C_{n}H_{2n+1}COOH and C_{n}H_{2n-2}COOH (n = 1-21, especially 17-21).

Other derivatives include complexes with phospholipids. Such complexes include compounds having the general formula

\[
\text{CH}_2\text{O}-R
\]
\[
\text{CH}_3\text{O}-R_1
\]
\[
\text{CH}_2\text{O}-\text{P}^+\text{O}^-
\]
\[
\text{CH}_2\text{O}-R_2^+
\]

wherein R and R_1, which can be the same or different are each an acyl residue of a C_{16-22} saturated or unsaturated fatty acid, and R_2 is -CH_2CH_2N(CH_3)_3, -CH_2CH_2NH_2, -CH_2CH_2(COOH)NH_2.
PHARMACOLOGICAL DATA

Bilobalide was subjected to the following tests:

1. *In vitro* Tests on schizomycetes

   Solutions of the substance in varying dilutions were added in equal parts to agarized Mueller-Hinton culture medium kept in a liquid state at 56°C, then poured into Petri dishes. After solidification, the dishes were surface sown with suspensions of schizomycetes recently isolated from pathological materials and incubated at 37°C in an atmosphere of CO₂ for 18 hours.

1.1. Tests on protozoa:

1.1.1 *Trichomomas vaginalis*

   Suspensions of the protozoon from cultures in Brain Heart Infusion Broth with 5% horse serum of material recently isolated from human pathological samples were distributed in portions of 200 μl/well in plastic plates with 20 wells containing bilobalide in scalar concentrations in physiological saline.

   The motility and multiplication of the protozoa were assessed from observation under an inverted microscope after various periods of incubation at 37°C in an atmosphere of CO₂.

1.1.2 *Pneumocystis carinii*

   Suspensions of the microorganism obtained from homogenised infected lung tissue were prepared in Minimal Medium (Eagle mod.) to which were added a solution of non-essential amino acids, 5% calf fetus serum and antibiotics. These solutions were sown onto cultures of HEL 229 fetal lung cells treated with solutions of the substance in MEM (Modified Essential Medium) in varying concentrations.

   After being incubated for various periods at 37°C in an atmosphere containing 5% CO₂, the cultures were fixed in methanol, stained with Giemsa and examined under the microscope to determine the parasite count. In this case, parallel tests were carried out with cotrimoxazole, the reference drug for tests on this microorganism.

2. *In vivo* tests - *Pneumocystis carinii*

   *In vivo* tests were conducted in rats treated with cortisone and infected pertracheally with suspensions of *Pneumocystis carinii*, which received 10-100 mg/kg bilobalide for 5 days. These doses were selected on the basis of pharmacokinetic and toxicological data. Other groups were treated with cotrimoxazole and others kept as controls.

   The surviving animals were sacrificed at the end of a subsequent observation period and the lungs examined for the presence of the parasite.

   The table below gives some of the data on the inhibitory effect on the growth of various schizomycetes:

3. *In vitro* tests

3.1. Effect of bilobalide on various schizomycetes

<table>
<thead>
<tr>
<th>Strains</th>
<th>Concentrations μg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>+++</td>
</tr>
<tr>
<td><em>Streptococcus faecalis</em></td>
<td>+++</td>
</tr>
<tr>
<td><em>Lactobacillus sp</em></td>
<td>±</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>++</td>
</tr>
</tbody>
</table>

+ = growth  
* = no growth
3.2 Effect of bilobalide on *Trichomonas vaginalis*

<table>
<thead>
<tr>
<th>Result after</th>
<th>0</th>
<th>0.05</th>
<th>0.5</th>
<th>5</th>
<th>50</th>
<th>500</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>B</td>
<td>B</td>
<td>B</td>
<td>B</td>
<td>B</td>
<td>B</td>
<td>B</td>
</tr>
<tr>
<td>10'</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>180'</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>18h</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>±</td>
</tr>
<tr>
<td>50h</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td>±</td>
<td>±</td>
</tr>
</tbody>
</table>

A = mobility (++++ = normal, - = absent)
B = morphology (++++ = normal, - = significantly altered)

3.3 *In vitro* effect of bilobalide on *Pneumocystis carinii*

<table>
<thead>
<tr>
<th>Days' incubation</th>
<th>0</th>
<th>6.3</th>
<th>12.5</th>
<th>25</th>
<th>500</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>B</td>
<td>B</td>
<td>B</td>
<td>B</td>
<td>B</td>
<td>B</td>
</tr>
<tr>
<td>1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>5</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>8</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

A = bilobalide
B = cotrimoxazole
+ = growth
- = no growth

4. *In vivo* effect of bilobalide on *Pneumocystis carinii* after intraperitoneal administration

<table>
<thead>
<tr>
<th>Dose in mg/Kg d x 5</th>
<th>0</th>
<th>10</th>
<th>100</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>A</td>
<td>B</td>
<td>A</td>
</tr>
<tr>
<td>B</td>
<td>B</td>
<td>A</td>
<td>B</td>
</tr>
<tr>
<td>bilobalide</td>
<td>10</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>cotrimoxazole</td>
<td>10</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

A = mortality, %
B = pulmonary lesions, %
Bilobalide has proved effective in man in doses of between 1 and 100 mg/kg.

Regarding other diseases of fungal or protozoal origin, bilobalide has proved effective in periodontal diseases of unknown origin that were resistant to conventional treatments based on antibiotics and antifungal agents.

For systemic treatment in animals and man, complexes of bilobalide with phospholipids already described in patent application (EP 0 441 279) have been found to be particularly effective since they exhibit greater bioavailability than the product in its free form. Complexes with distearoyl phosphatidyl choline or natural phosphatidyl choline extracted from soya are of particular value.

Bilobalide and its complexes can be incorporated in standard pharmaceutical formulations: ampoules, hard and soft gelatine capsules, tablets, suppositories, vaginal pessaries, creams and ointments. Bilobalide or its related complexes can be used in treating a wide range of infections, alone and in combination therapies with other antibiotics.

Bilobalide may be formulated with conventional excipients and carriers, particularly those adapted for administration in the milieux specifically referred to herein. Specific examples of pharmaceutical formulations, and excipients and preservatives may be found in standard textbooks of pharmacology, e.g. Remington, etc.

Claims

1. The use of bilobalide or of a pharmacologically acceptable derivative thereof in the manufacture of a pharmaceutical composition for treating an infection in an individual.

2. The use of claim 1 wherein the infection is with an organism selected from Trichomonas vaginalis, Staphylococcus aureus, Streptococcus faecalis, Escherichia coli, Lactobacillus sp., Pneumocystis carinii.

3. The use of bilobalide or of a pharmacologically acceptable derivative thereof in the manufacture of a pharmaceutical composition for treating a vaginal infection in an individual, wherein said treatment comprises administering an effective dose of bilobalide or of a pharmacologically acceptable derivative thereof to the vagina.

4. The use claimed in Claim 3 wherein the composition is adapted for administration of the bilobalide in the form of a pessary or vaginal suppository, or as a cream or gel adapted for vaginal administration.

5. The use of bilobalide or of a pharmacologically acceptable derivative thereof in the manufacture of a pharmaceutical composition for treating an infection in an individual with Pneumocystis carinii.

6. The use of bilobalide or of a pharmacologically acceptable derivative thereof in the manufacture of a pharmaceutical composition for treating a pulmonary infection in an individual, especially an individual suffering an infection with Pneumocystis carinii.

7. The use of bilobalide or of a pharmacologically acceptable derivative thereof in the manufacture of a pharmaceutical composition for treating a periodontal infection in an individual.

8. The use claimed in Claim 7, wherein the bilobalide or pharmacologically acceptable derivative thereof is in the form of a toothpaste, mouth-wash or other orally acceptable composition.

9. The use according to any preceding claim wherein said pharmacologically acceptable derivatives are esters in which one or both of the hydroxy groups of bilobalide are esterified with a C2-22 carboxylic acid.

10. The use according to Claim 9 wherein the C2-22 carboxylic acids are selected from C2-22 alkanoic acids, C2-22 alkanedioic acids and C2-22 alkadienoic acids having the formulae CnH2n+1COOH, CnH2n−1COOH and CnH2n−3COOH (n = 1-21).

11. The use according to Claim 10 wherein n is from 17 to 21.

12. The use according to any of Claims 1 to 11 wherein said pharmacologically acceptable derivatives are complexes with phospholipids.

13. The use according to Claim 12 wherein said complexes have the formula
wherein \( R \) and \( R_1 \), which can be the same or different are each an acyl residue of a \( C_{16-22} \) saturated or unsaturated fatty acid, and \( R_2 \) is \(-\text{CH}_2\text{CH}_2\text{N}^+(\text{CH}_3)_3\), \(-\text{CH}_2\text{CH}_2\text{NH}_2\), \(-\text{CH}_2\text{CH}_2\text{(COOH)}\text{NH}_2\)

**Patentansprüche**


2. Verwendung nach Anspruch 1, wobei die Infektion mit einem Organismus, ausgewählt aus Trichomonas vaginalis, Staphylococcus aureus, Streptococcus faecalis, Escherichia coli, Lactobacillus sp., Pneumocystis carinii, erfolgte.


4. Verwendung nach Anspruch 3, wobei die Zusammensetzung zur Verabreichung des Bilobalids in Form eines Pessars oder vaginalen Suppositoriums ausgelegt ist oder als eine Creme oder ein Gel zur vaginalen Verabreichung ausgelegt ist.


8. Verwendung nach Anspruch 7, wobei das Bilobalid oder das pharmakologisch verträgliche Deriat davon in Form einer Zahnpaste, eines Mundwassers oder einer anderen oral verträglichen Zusammensetzung vorliegt.

9. Verwendung nach einem vorangehenden Anspruch, wobei die pharmakologisch verträglichen Derivate Ester darstellen, in denen eine oder beide der Hydroxygruppen von Bilobalid mit einer \( C_{2,22}^- \)-Carbonsäure verestert sind.

10. Verwendung nach Anspruch 9, wobei die \( C_{2,22}^- \)-Carbonsäuren ausgewählt sind aus \( C_{2,22}^- \)-Alkansäuren, \( C_{2,22}^- \)-Alkensäuren und \( C_{2,22}^- \)-Alkadiensäuren der Formeln \( C_n\text{H}_{2n+1}\text{COOH}, C_{n+1}\text{H}_{2n+1}\text{COOH} \) und \( C_{n+2}\text{H}_{2n+3}\text{COOH} (n = 1-21) \).

11. Verwendung nach Anspruch 10, wobei \( n = 17 \) bis 21 ist.

12. Verwendung nach einem der Ansprüche 1 bis 11, wobei die pharmakologisch verträglichen Derivate Komplexe mit Phospholipiden darstellen.

13. Verwendung nach Anspruch 12, wobei die Komplexe die Formel
aufweisen, worin R und R₁, die gleich oder verschieden sein können, jeweils einen Acylrest einer gesättigten oder ungesättigten C₁₆-₂₂-Fettsäure darstellen und R₂ -CH₂CH₂N⁺(CH₃)₂, -CH₂CH₂NH₂, -CH₂CH₂(COOH)NH₂ darstellt.

Revendications

1. Utilisation du bilobalide ou d’un dérivé de celui-ci acceptable du point de vue pharmacologique dans la fabrication d’une composition pharmaceutique pour le traitement d’une infection chez un individu.

2. Utilisation suivant la revendication 1, dans laquelle l’infection est par un organisme choisi parmi *Trichomonas vaginalis*, *Staphylococcus aureus*, *Streptococcus faecalis*, *Escherichia coli*, *Lactobacillus sp.*, *Pneumocystis carinii*.

3. Utilisation du bilobalide ou d’un dérivé de celui-ci acceptable du point de vue pharmacologique dans la fabrication d’une composition pharmaceutique pour le traitement d’une infection vaginale chez un individu, dans laquelle ce traitement comprend l’administration dans le vagin d’une dose efficace de bilobalide ou d’un dérivé de celui-ci acceptable du point de vue pharmacologique.

4. Utilisation suivant la revendication 3, dans laquelle la composition est adaptée à l’administration du bilobalide sous la forme d’un pessaire ou d’un suppositoire vaginal, ou sous forme de crème ou de gel adapté à l’administration vaginale.

5. Utilisation du bilobalide ou d’un dérivé de celui-ci acceptable du point de vue pharmacologique dans la fabrication d’une composition pharmaceutique pour le traitement d’une infection d’un individu par *Pneumocystis carinii*.

6. Utilisation du bilobalide ou d’un dérivé de celui-ci acceptable du point de vue pharmacologique dans la fabrication d’une composition pharmaceutique pour le traitement d’une infection pulmonaire chez un individu, en particulier un individu souffrant d’une infection par *Pneumocystis carinii*.

7. Utilisation du bilobalide ou d’un dérivé de celui-ci acceptable du point de vue pharmacologique dans la fabrication d’une composition pharmaceutique pour le traitement de périodontite chez un individu.

8. Utilisation suivant la revendication 7, dans laquelle le bilobalide ou un dérivé de celui-ci acceptable du point de vue pharmacologique de celui-ci est sous la forme d’une pâte dentifrice, d’un collutioire ou d’une autre composition acceptable oralement.

9. Utilisation suivant l’une quelconque des revendications précédentes, dans laquelle ces dérivés acceptables du point de vue pharmacologique sont des esters dans lesquels un ou les deux groupes hydroxy du bilobalide sont estérifiés avec un acide carboxylique en C₂₂-2₂.

10. Utilisation suivant la revendication 9, dans laquelle les acides carboxyliques en C₂₂-2₂ sont choisis parmi les acides alcanoliques en C₂₂-2₂, les acides alcénoïques en C₂₂-2₂ et les acides alcanédioniques en C₂₂-2₂, ayant les formules CₙH₂ₙ⁻₁COOH, CₙH₂ₙ⁻₁COOH et CₙH₂ₙ⁺₃COOH (n = 1 à 21).

11. Utilisation suivant la revendication 10, dans laquelle n est de 17 à 21.

12. Utilisation suivant l’une quelconque des revendications 1 à 11, dans laquelle ces dérivés acceptables du point de vue pharmacologique sont des complexes formés avec des phospholipides.
13. Utilisation suivant la revendication 12, dans laquelle ces complexes ont la formule :

\[
\begin{align*}
&\text{CH}_2-O-R \\
&\text{CH}-O-R_1 \\
&\text{CH}_2-O-P^\delta-O-R_2
\end{align*}
\]

\[
\begin{align*}
&\text{H} \\
&\text{O} \\
&\text{O} \\
&\text{O} \\
&\text{O} \\
&\text{c(CH}_3\text{)}_3
\end{align*}
\]

dans laquelle R et R₁, qui peuvent être identiques ou différents, sont chacun un résidu acyle d'un acide gras saturé ou insaturé en C₁₆₋₂₂, et R₂ est un groupe choisi parmi -CH₂CH₂N⁺(CH₃)₃, -CH₂CH₂NH₂, et -CH₂CH₂(COOH)NH₂.